The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-UK says vaccine roll-out to be slower than hoped, but should pick up again in May

Thu, 18th Mar 2021 07:17

* UK says global lumpy supply chain causing issues

* UK vaccine roll-out will be slower than hoped

* UK says vaccine deliveries to rise from May

* UK scolds EU over vaccine ban threat
(Adds comment from Serum Institute, Moderna)

By Guy Faulconbridge, Kate Holton and Alistair Smout

LONDON, March 18 (Reuters) - Britain said on Thursday that
global supply bumps meant its vaccine roll-out would be slower
than hoped in coming weeks but it expected deliveries to
increase again in May, June and July.

British health officials warned on Wednesday that the
world's fastest big economy roll-out of the vaccine would face a
significant reduction in supplies from March 29, though they did
not say where the problems were.

Pfizer Inc and AstraZeneca Plc said their
delivery schedules had not been impacted, and Housing Secretary
Robert Jenrick refused to be drawn on whether the issue was due
to a problem with supply from India.

"We have less supply than we might have hoped for the coming
weeks but we expect it to increase again later," Jenrick told
the BBC.

"The vaccine roll-out will be slightly slower than we might
have hoped but not slower than the target," he said. "We have
every reason to believe that supply will increase in the months
of May, June and July."

Britain is on track to have given a first shot to half of
all adults in the next few days, making it one of the fastest
countries to roll out a vaccine.

So far 25.27 million people in the United Kingdom have had a
vaccine, around 48% of adults, and Jenrick said Britain remained
on track to have vaccinated priority groups by April 15 and all
adults by the end of July.

"We always said right from the beginning that a new
manufacturing process would have its lumps and bumps and that
has been the case in the past and I'm sure it will be in the
future," Jenrick told Sky.

"We're sourcing vaccines from all over the world and we are
experiencing occasionally some issues and that's led to this,
this issue with some supply in the coming weeks," he said.

Asked if the issue was supply from India, he declined to
discuss specific contracts.

SUPPLY BUMP

Britain is rolling out vaccines made by Pfizer and
AstraZeneca, with 10 million doses of the 100 million ordered
from AstraZeneca coming from the Serum Institute in India.

"Five million doses had been delivered a few weeks ago to
the UK and we will try to supply more later, based on the
current situation and requirement for the Government
immunisation programme in India," a spokesman for the Serum
Institute said.

An AstraZeneca spokesman said: "Our UK domestic supply chain
is not experiencing any disruption and there is no impact on our
delivery schedule."

Pfizer, which supplies Britain with shots from Europe, said
first-quarter deliveries to the UK remained on track and overall
supply for the second quarter remained unchanged. Moderna said
it was expecting first deliveries of its own vaccine to Britain
to start in April.

The announcement of a supply shortfall coincided with a
resurgence in tensions with the European Union, which is
frustrated by a lack of exports of AstraZeneca's vaccine from
Britain.

The EU threatened on Wednesday to ban exports of COVID-19
vaccines to Britain to safeguard scarce doses for its own
citizens, and Jenrick said the threat from European Commission
head Ursula von der Leyen was disappointing.

"I was surprised and disappointed by those comments but the
prime minister had spoken earlier in the year to Ursula von der
Leyen and she gave a very clear commitment, which was that the
EU would not engage in this sort of activity, that contractual
responsibilities would be honoured," Jenrick said.

"And that's exactly what we intend to do and I hope and
expect the EU to stick to their side of the bargain."
(Reporting by Guy Faulconbridge, Kate Holton and Alistair Smout
in London; additional reporting by Krishna N. Das in New Delhi;
editing by Sarah Young, Giles Elgood and Nick Macfie)

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.